AzTrials
AzTrials

DiabetesHypoArrhythmiaNCT02778269

Predicting Hypoglycaemia and Arrhythmias in the Patient With Diabetes and CKD - Validation Study

A study testing 12-lead ECG T-shirt and Dexcom G4-System in people with Diabetes and Hypoglycaemia, run by RWTH Aachen University at 1 site in Germany.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Patients with insulin-dependent diabetes mellitus (DM) and chronic kidney disease (CKD) exhibit an excessive risk for cardiac arrhythmias, in particular sudden cardiac death (SCD). Read more about this study

Who is it for?
Ages 18 years and older, men only
Conditions the study is for
Diabetes, Hypoglycaemia, Chronic Kidney Disease
What is being tested?
12-lead ECG T-shirt and Dexcom G4-System
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
7 participants
Where
1 siteGermany
Study dates
Jun 2016to Mar 2017
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Men only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Insulin-treated diabetes mellitus (type 1 or 2)
  • CKD with eGFR < 45 ml/min, determined using the Modification of Diet in Renal Disease (MDRD) formula
  • Stable anti-diabetic and cardiac medication prior to inclusion
  • Male aged ≥ 18 years
  • Written informed consent prior to study participation
  • Adults who are contractually capable and mentally able to understand and follow the instructions of the study personnel.

Who cannot join

  • Pregnancy or women without sufficient contraception, adapted specifically to amenorrhoeic hemodialysis patients
  • Life expectancy below 6 months
  • Participation in another clinical trial within the previous 2 months
  • History of any other illness, which, in the opinion of the investigator, might pose an unacceptable risk when administering study medication
  • Any current or past medical condition and/or required medication to treat a condition that could affect the evaluation of the study
  • Alcohol or drug abuse
Show all 11Show fewer
  • Patient has been committed to an institution by legal or regulatory order
  • Patients with any kind of pacemakers
  • Expected non-compliance
  • Patients unwilling or unable to give informed consent, or with limited ability to comply with instructions for this study
  • Participation in a parallel interventional clinical trial

Trial locations and contacts

1 site in 1 country.

Germany1 site
  • Medizinische Klinik I

    Aachen, North Rhine-Westphalia, 52074

Other trials in Germany

About this study

Official title: Predicting Hypoglycaemia and Arrhythmias in the Vulnerable Patient With Diabetes and Chronic Kidney Disease - Validation Study

Patients with insulin-dependent diabetes mellitus (DM) and chronic kidney disease (CKD) exhibit an excessive risk for cardiac arrhythmias, in particular sudden cardiac death (SCD). Various studies have shown that hypoglycemic episodes are strong predictors of cardiovascular mortality in both type 1 and type 2 diabetic patients. Experimental data and small clinical studies link hypoglycemia with ECG changes and SCD, but little is known about the direct association of hypoglycemic events and/or rapid swings in blood glucose with arrhythmias in this high risk population. Ideally, an algorithm should help to identify patients at risk for hypoglycemia-associated arrhythmias and SCD, but hitherto systematic analyses of blood glucose values and 12-channel ECGs are lacking in these patients.

In this validation study a 12-lead ECG T-shirt consisting of textile electrodes and a data logging device wich can record long-term 12-lead ECG data will be tested. The purpose of the T-shirt is to improve the patient's comfort for long-term recordings and to prevent adverse effects of regular ECG electrodes. Current systems are limited by the use of ECG electrodes involving disadvantages like severe direct side effects on the skin such as rash and bullous lesions as well as slipping electrodes. By the means of the proposed ECG T-shirt those drawbacks will be avoided.

Read the detailed description

Patients with diabetes mellitus (DM), especially those with a long duration of diabetes, insulin treatment and chronic kidney disease (CKD) are vulnerable patients exhibiting a high risk for cardiac arrhythmias and sudden cardiac death (SCD). Various factors such as the presence of coronary heart disease, diabetic cardiomyopathy as well autonomic neuropathy are underlying pathologies associated with the development of potentially fatal arrhythmias in these patients while hypoglycemic events are considered to directly trigger these arrhythmias. It has been postulated that severe hypoglycemia may lead to cardiac arrhythmias, later summarized as the "dead in bed" syndrome. In addition, recent data from large cardiovascular outcome trials in patients with type 2 diabetes suggest that severe hypoglycemia is associated with an increased risk of cardiovascular events and cardiovascular related death. Moreover, CKD markedly increases the risk for hypoglycemia and even a moderate impairment of kidney function (eGFR < 45 ml/min) is associated with a significant increase in SCD.

Various pathophysiological mechanisms may contribute to the increased cardiovascular mortality after hypoglycemia including hypoglycemia-induced release of catecholamines, pro-arrhythmogenic ECG alterations as well as inflammatory changes. Morphological and functional alterations of the heart occurring in CKD further contribute to these mechanisms. So far performed studies were limited by a short duration of glucose and ECG monitoring and by the fact that only 3 lead Holter-ECGs were used, thus not allowing the assessment of more sophisticated ECG abnormalities such as QT dispersion, T-wave alternans, or late potentials. Therefore no clear data exist to predict arrhythmias and SCD and its relation to hypoglycemia in patients with diabetes. Ideally, a SCD risk score could identify and characterize high-risk patients but to date little is known about hypoglycemia-associated ECG markers for the identification of patients at risk for arrhythmias and SCD.

In the general population, various ECG risk markers for SCD have been identified such as heart rate, cardiac rhythm abnormalities, atrioventriculare (AV) block, QT length, QT dispersion, heart-rate variability (HRV), T-wave alternans, late potentials, as well as left- (LBBB) or right-bundle branch block (RBBB) (reviewed in). In patients with diabetes hypoglycemia, diabetic cardiomyopathy, as well as the presence of autonomic neuropathy may lead to such ECG abnormalities. Merely sparse data exist on the effect of spontaneous hypoglycemic episodes and changes in ECG parameters with only a small study in patients with type 1 diabetes demonstrating that nocturnal hypoglycemia is associated with a decrease in the low-frequency component of heart rate variability. To date, more sophisticated markers such as QT dispersion, late potentials, or T-wave alternans were not examined in a "real-life setting", most likely because these markers require a 12 lead ECG registration of longer duration.

However, for the establishment of a risk algorithm for the prediction of hypoglycemia-associated arrhythmias it is mandatory to perform long duration simultaneous glucose monitoring and 12 lead ECG registration to capture these ECG risk markers for SCD.

In an actually running project the investigators are evaluating the association of hypoglycemic events/glucose swings and arrhythmias/ECG predictors for SCD a clinical study will be performed in 50 patients with insulin-treated diabetes and moderate to severe CKD. These patients receive 7 days continuous glucose and ECG registration and data will be used for the development of the risk assessment model.

The current validation study seeks to confirm the risk assessment model developed in collaboration with AICES - Aachen Institute for Advanced Study in Computational Engineering Science and to approve the capacitive ECG registration device obtained in collaboration with Philips Chair for Medical Information Technology at University Clinical Center Aachen (UKA). To this end, 10 patients with insulin-treated diabetes and moderate to severe CKD will be included. Seven day glucose monitoring as well as data of capacitive ECG recordings will be generated in this study, thus allowing validation and adjustment of the developed medical hardware and the mathematic models. The study item is a 12-lead ECG T-shirt consisting of textile electrodes and a data logging device. The device can record long-term 12-lead ECG data. The purpose of the T-shirt is to improve the patient's comfort for long-term recordings and to prevent adverse effects of regular ECG electrodes. Current systems are limited by the use of ECG electrodes, which are hardly tolerated by the patients because of severe direct side effects on the skin such as rash and bullous lesions. These side effects are a result of skin preparation and electrode gel. The proposed ECG T-shirt does not need these problematic preparations. Another benefit is the fixed placement of the electrodes on the T-shirt. In regular 12-lead ECG long-term recordings, the electrodes may fall off and the patient needs to reattach them. Therefore, faulty positioning of the electrodes may occur.

Being tested
12-lead ECG T-shirt, Dexcom G4-System
Keywords
ECG, CGM, Hypoglycaemia, Sudden Cardiac Death
Medical subject headings
Diabetes Mellitus, Hypoglycemia, Renal Insufficiency, Chronic, Death, Sudden, Cardiac

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 12-lead ECG T-shirtDevice

    The 12-lead ECG T-shirt system consists of three parts: the recording device, amplifier boards and the T-shirt.The T-shirt has 10 textile ECG electrode patches. The patches should be in contact with the patient's skin to record the electrical activity of the heart. The electrodes are made of electrically conductive textile. They are sewn into the inside of the T-shirt and are padded with foam. The cables to the device can be attached to snap fasteners on the outer side of the T-shirt on the ECG electrode patches.

  • Dexcom G4-SystemDevice

    Also called CGM

    Continuous Glucose Monitoring

Study groups in NCT02778269
Study groupRoleWhat they receive
Study TreatmentExperimentalThe patients wear a 12-lead ECG T-shirt for 7 days. During this time period ECG data are measured continuously. In addition the continous glucose monitoring system (CGM) records glucose levels via Dexcom G4-System.
Receives: Device: 12-lead ECG T-shirt; Device: Dexcom G4-System

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. QRS duration [sec]

    Prolonged duration indicates e.g. hyperkalemia or bundle branch block.

    Measured: 7 days

  2. QRS amplitude [mV]

    Increased amplitude indicates cardiac hypertrophy.

    Measured: 7 days

  3. Ventricular activation time (VAT) [sec]

    Measured in increased QRS amplitude.

    Measured: 7 days

  4. Number of power-line interference on the ECG

    Feasibility of the 12-lead ECG T-shirt: movements of the t-shirt might cause power-line interferences on the ECG.

    Measured: 7 days

Secondary outcomes (1)
  1. Number of congruences concerning identified arrhythmias of this validation study and the previous study "Predicting Hypoglycaemia and Arrhythmias in the vulnerable Patient with Diabetes and Chronic Kidney Disease".

    The number of congruences of this validation study and the previous study will validate the developed mathematic risk assessment model.

    Measured: 7 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 May 2016 (estimated)
  2. Study startJun 2016
  3. Primary completionMar 2017
  4. Study completionMar 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
7 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02778269
Sponsor's protocol ID
14-030 MPG
Acronym
HypoArrhythmia
Status last verified
Aug 2016
First submitted
9 May 2016
Last updated
7 Apr 2017
Results posted
No
Data monitoring committee
No
Individual data sharing
No

Publications

  • Causes of death. USRDS. United States Renal Data System. Am J Kidney Dis. 1997 Aug;30(2 Suppl 1):S107-17. No abstract available.

    PubMed 9259696
  • Carrero JJ, de Mutsert R, Axelsson J, Dekkers OM, Jager KJ, Boeschoten EW, Krediet RT, Dekker FW; NECOSAD Study Group. Sex differences in the impact of diabetes on mortality in chronic dialysis patients. Nephrol Dial Transplant. 2011 Jan;26(1):270-6. doi: 10.1093/ndt/gfq386. Epub 2010 Jul 9.

    PubMed 20621930
  • Tattersall RB. Brittle diabetes revisited: the Third Arnold Bloom Memorial Lecture. Diabet Med. 1997 Feb;14(2):99-110. doi: 10.1002/(SICI)1096-9136(199702)14:23.0.CO;2-I.

    PubMed 9047086
  • Gill GV, Woodward A, Casson IF, Weston PJ. Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes--the 'dead in bed' syndrome revisited. Diabetologia. 2009 Jan;52(1):42-5. doi: 10.1007/s00125-008-1177-7. Epub 2008 Oct 30.

    PubMed 18972096
  • Rana OA, Byrne CD, Greaves K. Intensive glucose control and hypoglycaemia: a new cardiovascular risk factor? Heart. 2014 Jan;100(1):21-7. doi: 10.1136/heartjnl-2013-303871. Epub 2013 May 22.

    PubMed 23697655
  • Shamseddin MK, Parfrey PS. Sudden cardiac death in chronic kidney disease: epidemiology and prevention. Nat Rev Nephrol. 2011 Mar;7(3):145-54. doi: 10.1038/nrneph.2010.191. Epub 2011 Feb 1.

    PubMed 21283136
  • Hanefeld M, Duetting E, Bramlage P. Cardiac implications of hypoglycaemia in patients with diabetes - a systematic review. Cardiovasc Diabetol. 2013 Sep 21;12:135. doi: 10.1186/1475-2840-12-135.

    PubMed 24053606
  • Giorgino F, Leonardini A, Laviola L. Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials. Ann N Y Acad Sci. 2013 Apr;1281(1):36-50. doi: 10.1111/nyas.12044. Epub 2013 Feb 6.

    PubMed 23387439
  • Schachinger H, Port J, Brody S, Linder L, Wilhelm FH, Huber PR, Cox D, Keller U. Increased high-frequency heart rate variability during insulin-induced hypoglycaemia in healthy humans. Clin Sci (Lond). 2004 Jun;106(6):583-8. doi: 10.1042/CS20030337.

    PubMed 14717655
  • Landstedt-Hallin L, Englund A, Adamson U, Lins PE. Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus. J Intern Med. 1999 Sep;246(3):299-307. doi: 10.1046/j.1365-2796.1999.00528.x.

    PubMed 10475998
  • Koivikko ML, Karsikas M, Salmela PI, Tapanainen JS, Ruokonen A, Seppanen T, Huikuri HV, Perkiomaki JS. Effects of controlled hypoglycaemia on cardiac repolarisation in patients with type 1 diabetes. Diabetologia. 2008 Mar;51(3):426-35. doi: 10.1007/s00125-007-0902-y. Epub 2007 Dec 19.

    PubMed 18097646
  • Junttila MJ, Castellanos A, Huikuri HV, Myerburg RJ. Risk markers of sudden cardiac death in standard 12-lead electrocardiograms. Ann Med. 2012 Nov;44(7):717-32. doi: 10.3109/07853890.2011.594807. Epub 2011 Jul 11.

    PubMed 21745092
  • Robinson RT, Harris ND, Ireland RH, Lee S, Newman C, Heller SR. Mechanisms of abnormal cardiac repolarization during insulin-induced hypoglycemia. Diabetes. 2003 Jun;52(6):1469-74. doi: 10.2337/diabetes.52.6.1469.

    PubMed 12765959
  • Koivikko ML, Tulppo MP, Kiviniemi AM, Kallio MA, Perkiomaki JS, Salmela PI, Airaksinen KE, Huikuri HV. Autonomic cardiac regulation during spontaneous nocturnal hypoglycemia in patients with type 1 diabetes. Diabetes Care. 2012 Jul;35(7):1585-90. doi: 10.2337/dc11-2120. Epub 2012 May 18.

    PubMed 22611064

Questions about this trial

What is this clinical trial studying?

A study testing 12-lead ECG T-shirt and Dexcom G4-System in people with Diabetes and Hypoglycaemia, run by RWTH Aachen University at 1 site in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 7 Apr 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

QRS duration [sec] (time frame: 7 days). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02778269, which also lists 14 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Apr 2017; AzTrials last refreshed its copy on 8 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in